W2J Stock Overview
A clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Carisma Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.80 |
| 52 Week High | US$2.82 |
| 52 Week Low | US$0.71 |
| Beta | 0 |
| 11 Month Change | -7.94% |
| 3 Month Change | -24.41% |
| 1 Year Change | -65.50% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 33.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| W2J | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.9% | -0.7% | -0.02% |
| 1Y | -65.5% | -17.2% | 8.2% |
Return vs Industry: W2J underperformed the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: W2J underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| W2J volatility | |
|---|---|
| W2J Average Weekly Movement | 8.2% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: W2J's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: W2J's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 107 | Steve Kelly | www.carismatx.com |
Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company’s ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases.
Carisma Therapeutics, Inc. Fundamentals Summary
| W2J fundamental statistics | |
|---|---|
| Market cap | €33.99m |
| Earnings (TTM) | -€61.27m |
| Revenue (TTM) | €19.46m |
1.7x
P/S Ratio-0.5x
P/E RatioIs W2J overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| W2J income statement (TTM) | |
|---|---|
| Revenue | US$20.27m |
| Cost of Revenue | US$63.51m |
| Gross Profit | -US$43.24m |
| Other Expenses | US$20.56m |
| Earnings | -US$63.80m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.53 |
| Gross Margin | -213.35% |
| Net Profit Margin | -314.78% |
| Debt/Equity Ratio | 0% |
How did W2J perform over the long term?
See historical performance and comparison